Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines

New York – July 27, 2025 – Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.

GSK will pay $500 million in upfront fees to Hengrui Pharma, with the potential for up to $12 billion in additional milestone payments if all programs are optioned and all milestones are achieved. Hengrui Pharma will also be eligible to receive tiered royalties on global product net sales, excluding mainland China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region and the Taiwan region.

Lawyers Alan Tamarelli, Frances Stocks Allen, Jiqiang Lin, Freddy Yip, Shawn Yu, David Burns, Julia Brinton, Aaron Pomeroy, Rick Jantz and Andrew Epstein led the Cooley team advising Hengrui Pharma.

Cooley previously advised Hengrui Pharma on its exclusive license agreement with Merck KGaA, Darmstadt, Germany, in April 2025; its exclusive license agreement with Merck for HRS-5346 in March 2025; its global license agreement (excluding Greater China) with Hercules CM Newco in May 2024; its exclusive worldwide (excluding mainland China) license agreement with Merck KGaA in October 2023; and its global license agreement (excluding Greater China and Korea) with Elevar Therapeutics in November 2023.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.